Abstract
Estrogen-signaling pathways are implicated in the development of breast cancer and prostate cancer. Various studies have focused on additional signaling pathways, mediated by estrogen-related receptors (ERRs). ERRs are constitutively active receptors that share a high degree of homology with the classical estrogen receptors (ERs). However, they do not bind to estrogen, while ERs do. ERRs are involved in the development of alternative pathways that lead to the development of cancer and are regarded as potential therapeutic targets for the treatment of breast cancer and prostate cancer that do not respond to conventional therapies. In this review, we first present general structural features of ERRs. Then, we focus on breast cancer and prostate cancer, which are primarily hormone-dependent cancers, and summarizes recent progress in elucidating the involvement of each ERR in these two types of malignancies.
Introduction
Among the 48 members of the nuclear receptor superfamily, the estrogen receptor (ER)-like subfamily (NR3) is one of the seven subfamilies and is composed of three groups: ERs(NR3A), estrogen-related receptors (ERRs or NR3B), and 3-ketosteroid receptors (NR3C), which include the androgen receptor (AR), progesterone receptor (PR), glucocorticoid receptor (GR), and mineralocorticoid receptor (MR). ERRs were initially thought to share a common biological function with ERs, but unexpectedly, they do not bind to estrogen or endogenous ER ligands and are considered orphan nuclear receptors (1).
Estrogens are natural hormones considered to play a major role in promoting the proliferation of both the normal and neoplastic breast epithelium. Growing evidences suggest that estrogen-signaling pathways are implicated in not only in the development of breast cancer but also in that of prostate cancer, which are both hormone-dependent cancers (2). ER-positive breast cancers are preferentially treated with antiestrogens such as selective ER modulators known as SERMs (including tamoxifen which is the most commonly used) or selective ER down-regulators known as SERDs (ICI 182,780) (3). Aromatase inhibitors are used in postmenopausal women to block the enzyme aromatase, which is involved in the final step of estrogen synthesis from circulating androgens (4). Androgen deprivation therapy (ADT) is used for the treatment of locally advanced, biochemically recurrent, and metastatic prostate cancer. However, after the initial response, these therapies for breast and prostate cancer fail and cancer will inevitably recur (5ā7). The mechanisms underlying recurrence have not been fully clarified, but the acquisition of alternative intracellular ER signaling may be involved in hormonal therapy resistance.
Various studies have focused on additional estrogen-related signaling pathways, mediated by ERRs (8ā10). Sequence analysis reveals that ERRs and the classical ERs share a high degree of homology within their DNA and ligand-binding domains (LBDs) (11). The ERR family consists of three closely related members: ERRĪ±, ERRĪ², and ERRĪ³ (Figure 1). ERRs, like other nuclear receptors, consist of six conserved regions (AāF): A/B domain containing the N-terminal domain (NTD), C domain with a DNA binding domain (DBD), D domain, which corresponds to the hinge region, E domain containing a putative LBD, and the F domain or C-terminal region. The transcriptional activation function-1 (AF-1) site is located in the N-terminal A/B domain, and its activity does not depend on the presence of activating ligands. The ligand-regulated activation function-2 (AF-2) site is located at E domain and it is known to synergize with AF-1 to regulate gene expression (12, 13). These receptors are constitutively active due to the structure of the LBD that leaves the AF-2 exposed and capable of binding coregulators in the absence of ligand binding.
Figure 1
ERR Action Mechanisms
Like other nuclear receptors, the transcriptional activity of ERRs is dependent on the presence of coregulatory proteins, either corepressors or coactivators. Steroid receptor coactivator (SRC)-1, -2, and -3, which regulate hepatic metabolism, fat storage, and energy balance, have been shown to interact with one or more ERR isoform stimulating their transcriptional activity (14, 15). PPARĪ³ coactivator (PGC)-1Ī± and PGC-1Ī², which play essential roles in metabolic programs, have been shown to directly interact with ERRs, positively regulating the expression and activity or these nuclear receptors (16). The activity of the ERRs as transcription factors is generally inhibited through physical interaction with receptor interacting protein 140, RIP140, also known as nuclear receptor interacting protein 1, NRIP1, a corepressor that competes for interaction with PGC-1Ī± for ERRs binding negatively regulating gene expression (17).
Estrogen-related receptors can bind to DNA on ERR response elements (ERREs) designated by the sequence 5ā²-TNAAGGTCA-3ā² as well as the classical ER response elements (EREs) 5ā²-AGGTCANNNTGACCT-3ā², where N represents any nucleotide (18ā20). These orphan nuclear receptors play a central role in regulating cellular metabolism through the regulation of genes involved in glycolysis, oxidative phosphorylation, and tricarboxylic acid cycle (21). ERRĪ± is present in tissues with high metabolism, such as the heart, kidney, intestinal tract, skeletal muscle, and brown adipose tissue (22). The expression of ERRĪ² and ERRĪ³ is more restricted, being mainly expressed in the heart and kidney (22, 23). Both ERRĪ± and ERRĪ³ are upregulated in preadipocytes and pluripotent mesenchymal cells under adipogenic conditions, positively regulating lipid accumulation (24, 25). ERRĪ² and ERRĪ³ are also expressed during the early embryonic development and in the central nervous system and spinal cord. Although ERRs have structural and functional similarities, mice deficient for each ERR exhibit different phenotypes, suggesting that these ERRs have specific and unique functions. ERRĪ±-deficient mice are viable, but exhibit a phenotype characterized by reduced body weight, peripheral fat deposits, and resistance to high-fat diet-induced obesity (26). They also exhibit a loss of normal mitochondrial biogenesis (27). On the other hand, ERRĪ²-deficient mice are lethal due to impaired placenta formation (28). Interestingly, an important role of this orphan receptor in embryonic stem (ES) cells maintenance has been suggested, as it is able to regulate self-renewal in ES cells in cooperation with octamer-binding protein 4, Oct4, and sex determining region Y-box 2, Sox2, replacing kruppel-like factor 4, Klf4, and consequently enhancing the transcription of reprograming factors (29). ERRĪ³-deficient mice also die during the early postnatal period due to abnormal heart function (30). It has been reported that ERR overexpression increases glycolysis, while depletion results in the opposite effect, reducing aerobic glycolysis (31). Furthermore, ERRĪ± and ERRĪ³ were found to form heterodimers and bind to the promoters of the same target genes to regulate genes controlling both the glycolytic and the oxidative mitochondrial respiration phenotypes (32). These findings suggest that ERRs might contribute to a shift in cellular metabolism from normal mitochondrial oxidative phosphorylation to an aerobic glycolysis typical of cancer cells, known as the Warburg effect, increasing glucose consumption, and ATP production (33). However, a number of evidence suggest that ERRĪ± and ERRĪ³ have opposite functions in regulating cellular metabolism. ERRĪ± could assist in setting a glycolytic profile required for the proliferation of rapidly dividing cells in normal tissues with high-energy demand and tumors consequently promoting cellular proliferation (34ā39). By contrast, ERRĪ³ high expression has been detected in tumors with better prognosis (36), and inhibition of this orphan receptor by a microRNA (miR-378*) induces a metabolic switch by promoting a Warburg-like phenotype (40). These findings illustrates the complexity of metabolic reprograming by ERRs in cancer cells, where ERRĪ± and ERRĪ³ could cooperate or play an opposite role in the metabolic transcriptional pathway depending on the cellular environment and the expression of distinct coregulators (41) (Table 1).
Table 1
| Receptor | Breast cancer | Prostate cancer | ||||
|---|---|---|---|---|---|---|
| Expression | Implication | Reference | Expression | Implication | Reference | |
| ERRĪ± (NR3B1) | High | Transcriptional activator or repressor | (42) | High | Promotion of cell growth | (39) |
| Promotion of cell growth and metastasis | (34, 39, 43, 44) | |||||
| ERRĪ² (NR3B2) | Uncertain | Uncertain | (36, 45) | Low | Inhibition of cell growth | (46) |
| ERRĪ³ (NR3B3) | High/low | Promotion or inhibition of cell growth | (36, 47, 48) | Low | Inhibition of cell growth | (49) |
Expression of ERR isoforms and implication in breast cancer and prostate cancer.
ERRs in Breast Cancer
Breast cancer is the leading cause of cancer-related death in women worldwide (50). It is primarily a hormone-dependent disease that can be regulated by the status of steroid hormones such as estrogen and progesterone. Unfortunately, the emergence of hormone-resistant tumor cells after years of treatment is a major issue affecting patients with breast cancer (7). Breast cancers can be divided into five subtypes that vary in their treatment options and survival outcomes based on gene expression profiles (51ā54). ERĪ± positive (ERĪ±+) and progesterone receptor positive (PR+) tumors account for approximately 70% of all cases (55, 56). These ERĪ±+/PR+ tumors can be further classified into HER2+ and HER2ā subtypes depending on epidermal growth factor receptor 2, ErbB-2, or HER2 gene expression. Blocking the estrogen production or estrogen binding to the receptor by tamoxifen or aromatase inhibitors is the standard treatment for both early and advanced ERĪ±+ breast cancer (57, 58). For ERĪ± negative (ERĪ±ā), progesterone receptor negative (PRā), and HER2+ (ERĪ±ā/PRā/HER2+) breast tumors, a combination of pertuzumab, trastuzumab, and docetaxel has been effective (59). However, there are still no approved targeted therapies for triple negative ERĪ±ā/PRā/HER2ābreast tumors (10ā17% of all breast cancer cases) (60, 61), or the normal breast-like or basal-like cancer subtype (15% of the cases) (62, 63), which are mostly triple negative and frequently have TP53 mutations (64).
Much attention has been paid to the role of ERRs in breast cancer, as they are orphan nuclear receptors closely related to ERs. ERRĪ± expression in breast tumors is often high, and it is expressed in tumors with poor prognosis (36). In samples from various cohorts of patients with breast cancer, ERRĪ± mRNA positively correlates with the expression of the oncogene ERBB2 and inversely correlates to that of ERĪ± and PR, which are considered as good prognostic markers for patients with breast cancer (36). The expression of ERRĪ± mRNA and protein positively correlates with the coactivator amplified in breast cancer 1 (AIB1), also known as SRC-3 (65). However, ERRĪ± is able to act as both a transcriptional activator and repressor depending on the cellular context, promoting or inhibiting tumor growth in breast cancer (42). In ERā breast cancer cells, ERRĪ± functions as a transcriptional activator constitutively interacting with coactivators and binding to EREs independently of any ligands. Consequently, ERRĪ± competes with ER in the regulation of estrogen-responsive genes such as the estrogen-regulated trefoil factor 1 (TFF1) (65, 66) and vascular endothelial growth factor (VEGF) (34, 43). In ER+ breast cancer cells, ERRĪ± functions as a transcriptional repressor, interacting with corepressors and binding to negative EREs (42).
ERRĪ± also plays a role in bone metastasis, which occurs in up to 70% of patients with advanced breast cancer (44). In a mouse xenograft model of metastatic human breast cancer, overexpression of wild-type ERRĪ±-reduced metastasis and breast cancer cell growth in the bone, likely by upregulating the osteoclastogenesis inhibitor, osteoprotegerin (OPG). By contrast, ERRĪ± overexpression increases breast cancer cell growth in the mammary gland and the expression of VEGF. Thus, ERRĪ± plays dual roles, promoting the progression and invasion of primary tumors by decreasing osteolytic lesions in the bone (44).
It has been suggested that the induction of c-myc expression by estrogen occurs through the ānon-classicalā pathway ā without binding of ERĪ± to its promoter (67). Another study demonstrated a positive correlation between ERRĪ±, c-myc, and aromatase (37), an enzyme that may enhance estrogen production and stimulate breast cancer progression (38). These studies propose that ERR could play an important role in alternative pathway to classical ERs-dependent pathway in cell signaling through aromatase and c-myc.
ERRĪ± participates in the enhancement of estrogen production by the activation of steroid sulfotransferase (SULT2A1), which maintains high level of peripheral dehydroepiandrosterone sulfate (DHEAS), an important dehydroepiandrosterone (DHEA) metabolite in estrogen synthesis in certain tissues (68). It has also been reported that SULT2A1 inactivates tamoxifen and raloxifene (69). Thus, SULT2A1 activation by ERRĪ± can partly explain the resistance of breast cancer cells expressing ERRĪ± to SERM therapy.
A clinical study analyzing 102 breast cancer samples revealed that the expression of ERRĪ± in more than 10% of malignant cells was associated with a 20% decrease in overall disease survival at 13āyears (70). In this work, association between ERĪ± and ERE-containing estrogen-responsive genes was markedly altered according to ERRĪ± status in breast cancer tissues, suggesting that ERRĪ± possibly modulates ERĪ±-mediated and ERE-dependent transcription, and changes the expression of estrogen-responsive genes in breast cancer cells. In a previous clinical study, high levels of ERRĪ± mRNA correlated with ERĪ±-tumor status in 38 tumor specimens (36). These two studies suggest that ERRĪ± mRNA and protein expression are associated with an unfavorable prognosis, and increase the risk of recurrence of breast cancer.
ERRĪ³ also acts differently depending on ER expression. In breast tumors co-expressing ER and PR, ERRĪ³ induces E-cadherin expression and promotes the mesenchymal-to-epithelial (MET) transition, resulting in the inhibition of tumor growth (36, 47). It has been shown that an AAAG tetranucleotide polymorphism in the untranslated region of the ERRĪ³ gene is associated with breast cancer predisposition (71), and that ERRĪ³ mediates tamoxifen resistance in invasive lobular breast cancer. In human breast cancer specimens, both ERRĪ³ mRNA and protein expression are upregulated compared with normal samples, and exogenously transfected ERRĪ³ increased breast cancer cell proliferation (36, 48). Tumors overexpressing ERRĪ³ are also frequently steroid receptor positive, which may reflect hormonal sensitivity and a preferable clinical outcome. Thus, ERRĪ³ mRNA expression is associated with a favorable prognosis of patients with breast cancer (36).
ERRĪ² expression has also been detected in breast tumors. It has been shown that ERRĪ² expression is associated with that of ERĪ², and that ERRĪ² levels inversely correlate with the S-phase fraction, suggesting that this orphan receptor inhibits cellular proliferation, or possibly promotes cellular differentiation (36). However, another report found that it acts as a proliferative gene (45). Thus, the potential role of ERRĪ² in breast cancer remains unclear.
ERRs in Prostate Cancer
Prostate cancer, which is dependent on androgens for proliferation and survival, is the second-leading cause of cancer-related mortality, after lung cancer, in men from developed countries (72). With early diagnosis, radical prostatectomy and/or radiation therapy are potentially curative. For advanced or metastatic prostate cancer, hormonal therapies, reducing androgen levels by surgical or chemical castration or inhibiting the AR protein by small molecules, are used (57). However, after an initial response, the cancer eventually recurs in an incurable, castration-resistant form (5, 6), as a result of amplification of AR protein, mutations of AR gene, and elevated production of AR variants (73).
In addition to androgen-signaling pathways, estrogen-signaling pathways are implicated in the development of prostate cancer (1), and estrogen has been used for the treatment of advanced prostate cancer (74). The direct effect of estrogens on normal and malignant prostate tissues is assumed to be mediated through ERĪ± and ERĪ² (75, 76).
ERRĪ± mRNA has been detected in prostate cancer cell lines and human prostate cancer tissue (77). Although a heterogeneous ERRĪ± staining was found in immunohistochemical analysis using prostate cancer tissues with low Gleason score (GS), increased ERRĪ± protein expression was detected in human prostate tissue from 106 surgical resected prostate samples in a study that showed a positive correlation between ERRĪ± expression and GS (78). The enhanced expression of ERRĪ± might play a role in the development of human prostate cancer and serve as a significant prognostic factor for the disease.
By contrast, reduced ERRĪ² and ERRĪ³ expression in some prostatic carcinomas has been reported (77), and overexpression of ERRĪ² or ERRĪ³ results in the suppression of cell proliferation in both androgen-sensitive and insensitive prostate cancer cells, suggesting that these receptors present antiproliferative or tumor-suppressing functions in prostate cancer (46, 49). Furthermore, it has been shown that ERRĪ² directly transactivates a promoter upstream of the cyclin-dependent kinase inhibitor, p21 gene, resulting in the inhibition of the cell cycle progression (46). Clinicopathological studies for the expression of both orphan receptors in human prostate tissues have been performed using immunohistochemical analysis (79). Cancerous lesions and benign foci obtained from radical prostatectomy were stained and immunoreactivity scores (IR scores) were evaluated from the proportion of immunoreactive cells and staining intensity, revealing that ERRĪ² and ERRĪ³ IR scores are significantly lower in cancerous tissues. In the same study, patients with high ERRĪ± IR score, but low ERRĪ³ IR score, presented a poorer cancer-specific survival when compared to the other group, suggesting that the expression of ERRĪ² and ERRĪ³ could be a useful prognostic indicator of prostate cancer (79).
ERRs Agonists and Antagonists
Although no endogenous ligands have been identified for these receptors several natural phytoestrogens (three isoflavones: genistein, daidzein, and biochanin A, and one flavone: 6, 3, 4-trihydroxyflavone) have been identified as potential ligands of these receptors with agonistic activities, by structure-based virtual screening and biological functional assays (80, 81). Phytoestrogens are produced by plants, and represent the major natural exogenous sources of estrogenic compounds. DY131 is another ERR agonist, specific to ERRĪ² and ERRĪ³ that was shown to enhance growth inhibition, which was caused by overexpression of these nuclear receptors (46, 49). Inhibition of ERRĪ± with the inverse agonist XCT790 reduces cell proliferation of various cancer cell lines, including prostate and breast cancer cells (39).
On the other hand, diethylstilbestrol (DB00255) and the tamoxifen metabolite, 4-hydroxytamoxifen, have been shown to interact with ERRĪ² and ERRĪ³ and act as antagonists (82, 83). SR16388, a novel steroidal antiestrogen, inhibits the interaction between its coactivator peroxisome proliferator-activated receptor Ī³ coactivator-1 Ī± to inhibit ERR Ī± activity (84).
Conclusion
Although the role of orphan nuclear receptors in cancer is becoming clearer as a result of advances in previous studies, their function still remains to be elucidated. A better understanding of ERRs in breast and prostate cancer will provide new insights into cancer biology as well as the discovery of novel small molecules that bind to these orphan receptors. This knowledge will be helpful for the identification of novel hormonal therapeutic strategies and cancer treatments.
Statements
Acknowledgments
We are grateful to Dr. K. Ikeda (Saitama Medical University) and Dr. K. Horie (Saitama Medical University) for critical reading of this manuscript and helpful suggestions. This work was supported by grants of the Cell Innovation Program and the P-DIRECT from the MEXT, Japan (SI), grants from JSPS, Japan (SI), and a grant of the Program for Promotion of Fundamental Studies in Health Sciences from NIBIO, Japan (SI). This work was supported by grants of the Cell Innovation Program (http://www.cell-innovation.org/) and the P-DIRECT (http://p-direct.mext.go.jp/) from the MEXT, Japan (S.I.), grants from JSPS KAKENHI (Grant Numbers 23249040 and 15K15353), Japan (S.I.), and a grant of the Program for Promotion of Fundamental Studies in Health Sciences from NIBIO (09-12), Japan (S.I.).
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
References
1
Roshan-MoniriMHsingMButlerMSCherkasovARenniePS. Orphan nuclear receptors as drug targets for the treatment of prostate and breast cancers. Cancer Treat Rev (2014) 40:1137ā52.10.1016/j.ctrv.2014.10.005
2
BonkhoffHBergesR. The evolving role of oestrogens and their receptors in the development and progression of prostate cancer. Eur Urol (2009) 55:533ā42.10.1016/j.eururo.2008.10.035
3
HowellSJJohnstonSRHowellA. The use of selective estrogen receptor modulators and selective estrogen receptor down-regulators in breast cancer. Best Pract Res Clin Endocrinol Metab (2004) 18:47ā66.10.1016/j.beem.2003.08.002
4
SmollichMGotteMFischgrabeJRadkeIKieselLWulfingP. Differential effects of aromatase inhibitors and antiestrogens on estrogen receptor expression in breast cancer cells. Anticancer Res (2009) 29:2167ā71.
5
EganADongYZhangHQiYBalkSPSartorO. Castration-resistant prostate cancer: adaptive responses in the androgen axis. Cancer Treat Rev (2014) 40:426ā33.10.1016/j.ctrv.2013.09.011
6
LonerganPETindallDJ. Androgen receptor signaling in prostate cancer development and progression. J Carcinog (2011) 10:20.10.4103/1477-3163.83937
7
RingADowsettM. Mechanisms of tamoxifen resistance. Endocr Relat Cancer (2004) 11:643ā58.10.1677/erc.1.00776
8
GiguereV. To ERR in the estrogen pathway. Trends Endocrinol Metab (2002) 13:220ā5.10.1016/S1043-2760(02)00592-1
9
HorardBVanackerJM. Estrogen receptor-related receptors: orphan receptors desperately seeking a ligand. J Mol Endocrinol (2003) 31:349ā57.10.1677/jme.0.0310349
10
YangNShigetaHShiHTengCT. Estrogen-related receptor, hERR1, modulates estrogen receptor-mediated response of human lactoferrin gene promoter. J Biol Chem (1996) 271:5795ā804.10.1074/jbc.271.10.5795
11
LaudetVHanniCCollJCatzeflisFStehelinD. Evolution of the nuclear receptor gene superfamily. EMBO J (1992) 11:1003ā13.
12
ToraLGronemeyerHTurcotteBGaubMPChambonP. The N-terminal region of the chicken progesterone receptor specifies target gene activation. Nature (1988) 333:185ā8.10.1038/333185a0
13
WarnmarkATreuterEWrightAPGustafssonJA. Activation functions 1 and 2 of nuclear receptors: molecular strategies for transcriptional activation. Mol Endocrinol (2003) 17:1901ā9.10.1210/me.2002-0384
14
KarmakarSFosterEASmithCL. Unique roles of p160 coactivators for regulation of breast cancer cell proliferation and estrogen receptor-alpha transcriptional activity. Endocrinology (2009) 150:1588ā96.10.1210/en.2008-1001
15
LiuDBenlhabibHMendelsonCR. cAMP enhances estrogen-related receptor alpha (ERRalpha) transcriptional activity at the SP-A promoter by increasing its interaction with protein kinase A and steroid receptor coactivator 2 (SRC-2). Mol Endocrinol (2009) 23:772ā83.10.1210/me.2008-0282
16
SkrzypczakMKapka-SkrzypczakLCyrankaMTreeckOWrobelAMatosiukD. Nuclear estrogen receptors co-activation mechanisms. Curr Med Chem (2013) 20:3317ā38.10.2174/09298673113209990006
17
TreuterEAlbrektsenTJohanssonLLeersJGustafssonJA. A regulatory role for RIP140 in nuclear receptor activation. Mol Endocrinol (1998) 12:864ā81.10.1210/mend.12.6.0123
18
PetterssonKSvenssonKMattssonRCarlssonBOhlssonRBerkenstamA. Expression of a novel member of estrogen response element-binding nuclear receptors is restricted to the early stages of chorion formation during mouse embryogenesis. Mech Dev (1996) 54:211ā23.10.1016/0925-4773(95)00479-3
19
SladekRBaderJAGiguereV. The orphan nuclear receptor estrogen-related receptor alpha is a transcriptional regulator of the human medium-chain acyl coenzyme A dehydrogenase gene. Mol Cell Biol (1997) 17:5400ā9.
20
BarryJBLaganiereJGiguereV. A single nucleotide in an estrogen-related receptor alpha site can dictate mode of binding and peroxisome proliferator-activated receptor gamma coactivator 1alpha activation of target promoters. Mol Endocrinol (2006) 20:302ā10.10.1210/me.2005-0313
21
DebloisGGiguereV. Oestrogen-related receptors in breast cancer: control of cellular metabolism and beyond. Nat Rev Cancer (2013) 13:27ā36.10.1038/nrc3396
22
BookoutALJeongYDownesMYuRTEvansRMMangelsdorfDJ. Anatomical profiling of nuclear receptor expression reveals a hierarchical transcriptional network. Cell (2006) 126:789ā99.10.1016/j.cell.2006.06.049
23
GiguereV. Transcriptional control of energy homeostasis by the estrogen-related receptors. Endocr Rev (2008) 29:677ā96.10.1210/er.2008-0017
24
IjichiNIkedaKHorie-InoueKYagiKOkazakiYInoueS. Estrogen-related receptor alpha modulates the expression of adipogenesis-related genes during adipocyte differentiation. Biochem Biophys Res Commun (2007) 358:813ā8.10.1016/j.bbrc.2007.04.209
25
KuboMIjichiNIkedaKHorie-InoueKTakedaSInoueS. Modulation of adipogenesis-related gene expression by estrogen-related receptor gamma during adipocytic differentiation. Biochim Biophys Acta (2009) 1789:71ā7.10.1016/j.bbagrm.2008.08.012
26
LuoJSladekRCarrierJBaderJARichardDGiguereV. Reduced fat mass in mice lacking orphan nuclear receptor estrogen-related receptor alpha. Mol Cell Biol (2003) 23:7947ā56.10.1128/MCB.23.22.7947-7956.2003
27
VillenaJAKralliA. ERRalpha: a metabolic function for the oldest orphan. Trends Endocrinol Metab (2008) 19:269ā76.10.1016/j.tem.2008.07.005
28
LuoJSladekRBaderJAMatthyssenARossantJGiguereV. Placental abnormalities in mouse embryos lacking the orphan nuclear receptor ERR-beta. Nature (1997) 388:778ā82.10.1038/42022
29
FengBJiangJKrausPNgJHHengJCChanYSet alReprogramming of fibroblasts into induced pluripotent stem cells with orphan nuclear receptor Esrrb. Nat Cell Biol (2009) 11:197ā203.10.1038/ncb1827
30
AlaynickWAKondoRPXieWHeWDufourCRDownesMet alERRgamma directs and maintains the transition to oxidative metabolism in the postnatal heart. Cell Metab (2007) 6:13ā24.10.1016/j.cmet.2007.06.007
31
CaiQLinTKamarajugaddaSLuJ. Regulation of glycolysis and the Warburg effect by estrogen-related receptors. Oncogene (2013) 32:2079ā86.10.1038/onc.2012.221
32
DufourCRWilsonBJHussJMKellyDPAlaynickWADownesMet alGenome-wide orchestration of cardiac functions by the orphan nuclear receptors ERRalpha and gamma. Cell Metab (2007) 5:345ā56.10.1016/j.cmet.2007.03.007
33
AoAWangHKamarajugaddaSLuJ. Involvement of estrogen-related receptors in transcriptional response to hypoxia and growth of solid tumors. Proc Natl Acad Sci U S A (2008) 105:7821ā6.10.1073/pnas.0711677105
34
SteinRAChangCYKazminDAWayJSchroederTWerginMet alEstrogen-related receptor alpha is critical for the growth of estrogen receptor-negative breast cancer. Cancer Res (2008) 68:8805ā12.10.1158/0008-5472.CAN-08-1594
35
ChangCYKazminDJasperJSKunderRZuercherWJMcDonnellDP. The metabolic regulator ERRalpha, a downstream target of HER2/IGF-1R, as a therapeutic target in breast cancer. Cancer Cell (2011) 20:500ā10.10.1016/j.ccr.2011.08.023
36
AriaziEAClarkGMMertzJE. Estrogen-related receptor alpha and estrogen-related receptor gamma associate with unfavorable and favorable biomarkers, respectively, in human breast cancer. Cancer Res (2002) 62:6510ā8.
37
JarzabekKKodaMKozlowskiLSulkowskiSKottlerMLWolczynskiS. The significance of the expression of ERRalpha as a potential biomarker in breast cancer. J Steroid Biochem Mol Biol (2009) 113:127ā33.10.1016/j.jsbmb.2008.12.005
38
YangCZhouDChenS. Modulation of aromatase expression in the breast tissue by ERR alpha-1 orphan receptor. Cancer Res (1998) 58:5695ā700.
39
BiancoSLanvinOTribolletVMacariCNorthSVanackerJM. Modulating estrogen receptor-related receptor-alpha activity inhibits cell proliferation. J Biol Chem (2009) 284:23286ā92.10.1074/jbc.M109.028191
40
EichnerLJPerryMCDufourCRBertosNParkMSt-PierreJet almiR-378(*) mediates metabolic shift in breast cancer cells via the PGC-1beta/ERRgamma transcriptional pathway. Cell Metab (2010) 12:352ā61.10.1016/j.cmet.2010.09.002
41
DebloisGSt-PierreJGiguereV. The PGC-1/ERR signaling axis in cancer. Oncogene (2013) 32:3483ā90.10.1038/onc.2012.529
42
KrausRJAriaziEAFarrellMLMertzJE. Estrogen-related receptor alpha 1 actively antagonizes estrogen receptor-regulated transcription in MCF-7 mammary cells. J Biol Chem (2002) 277:24826ā34.10.1074/jbc.M202952200
43
SteinRAGaillardSMcDonnellDP. Estrogen-related receptor alpha induces the expression of vascular endothelial growth factor in breast cancer cells. J Steroid Biochem Mol Biol (2009) 114:106ā12.10.1016/j.jsbmb.2009.02.010
44
FradetASorelHBouazzaLGoehrigDDepalleBBellahceneAet alDual function of ERRalpha in breast cancer and bone metastasis formation: implication of VEGF and osteoprotegerin. Cancer Res (2011) 71:5728ā38.10.1158/0008-5472.CAN-11-1431
45
LuDKiriyamaYLeeKYGiguereV. Transcriptional regulation of the estrogen-inducible pS2 breast cancer marker gene by the ERR family of orphan nuclear receptors. Cancer Res (2001) 61:6755ā61.
46
YuSWongYCWangXHLingMTNgCFChenSet alOrphan nuclear receptor estrogen-related receptor-beta suppresses in vitro and in vivo growth of prostate cancer cells via p21(WAF1/CIP1) induction and as a potential therapeutic target in prostate cancer. Oncogene (2008) 27:3313ā28.10.1038/sj.onc.1210986
47
TirabyCHazenBCGantnerMLKralliA. Estrogen-related receptor gamma promotes mesenchymal-to-epithelial transition and suppresses breast tumor growth. Cancer Res (2011) 71:2518ā28.10.1158/0008-5472.CAN-10-1315
48
IjichiNShigekawaTIkedaKHorie-InoueKFujimuraTTsudaHet alEstrogen-related receptor gamma modulates cell proliferation and estrogen signaling in breast cancer. J Steroid Biochem Mol Biol (2011) 123:1ā7.10.1016/j.jsbmb.2010.09.002
49
YuSWangXNgCFChenSChanFL. ERRgamma suppresses cell proliferation and tumor growth of androgen-sensitive and androgen-insensitive prostate cancer cells and its implication as a therapeutic target for prostate cancer. Cancer Res (2007) 67:4904ā14.10.1158/0008-5472.CAN-06-3855
50
JemalABrayFCenterMMFerlayJWardEFormanD. Global cancer statistics. CA Cancer J Clin (2011) 61:69ā90.10.3322/caac.20107
51
PerouCMSorlieTEisenMBvan de RijnMJeffreySSReesCAet alMolecular portraits of human breast tumours. Nature (2000) 406:747ā52.10.1038/35021093
52
Reis-FilhoJSWestburyCPiergaJY. The impact of expression profiling on prognostic and predictive testing in breast cancer. J Clin Pathol (2006) 59:225ā31.10.1136/jcp.2005.028324
53
RouzierRWagnerPMorandiPPusztaiL. Gene expression profiling of primary breast cancer. Curr Oncol Rep (2005) 7:38ā44.10.1007/s11912-005-0024-y
54
SorlieTPerouCMTibshiraniRAasTGeislerSJohnsenHet alGene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A (2001) 98:10869ā74.10.1073/pnas.191367098
55
AndersonWFChatterjeeNErshlerWBBrawleyOW. Estrogen receptor breast cancer phenotypes in the surveillance, epidemiology, and end results database. Breast Cancer Res Treat (2002) 76:27ā36.10.1023/A:1020299707510
56
NiemeierLADabbsDJBeriwalSStriebelJMBhargavaR. Androgen receptor in breast cancer: expression in estrogen receptor-positive tumors and in estrogen receptor-negative tumors with apocrine differentiation. Mod Pathol (2010) 23:205ā12.10.1038/modpathol.2009.159
57
DamberJEAusG. Prostate cancer. Lancet (2008) 371:1710ā21.10.1016/S0140-6736(08)60729-1
58
MohamedAKrajewskiKCakarBMaCX. Targeted therapy for breast cancer. Am J Pathol (2013) 183:1096ā112.10.1016/j.ajpath.2013.07.005
59
SwainSMBaselgaJKimSBRoJSemiglazovVCamponeMet alPertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer. N Engl J Med (2015) 372:724ā34.10.1056/NEJMoa1413513
60
BauerKRBrownMCressRDPariseCACaggianoV. Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California Cancer Registry. Cancer (2007) 109:1721ā8.10.1002/cncr.22618
61
CriscitielloCAzimHAJrSchoutenPCLinnSCSotiriouC. Understanding the biology of triple-negative breast cancer. Ann Oncol (2012) 23(Suppl 6):vi13ā8.10.1093/annonc/mds188
62
Reis-FilhoJSTuttAN. Triple negative tumours: a critical review. Histopathology (2008) 52:108ā18.10.1111/j.1365-2559.2007.02889.x
63
Cancer Genome Atlas Network. Comprehensive molecular portraits of human breast tumours. Nature (2012) 490:61ā70.10.1038/nature11412
64
PerouCM. Molecular stratification of triple-negative breast cancers. Oncologist (2011) 16(Suppl 1):61ā70.10.1634/theoncologist.2011-S1-61
65
HeckSRomJThewesVBeckerNBlumeBSinnHPet alEstrogen-related receptor alpha expression and function is associated with the transcriptional coregulator AIB1 in breast carcinoma. Cancer Res (2009) 69:5186ā93.10.1158/0008-5472.CAN-08-3062
66
SurowiakPMaternaVGyorffyBMatkowskiRWojnarAMaciejczykAet alMultivariate analysis of oestrogen receptor alpha, pS2, metallothionein and CD24 expression in invasive breast cancers. Br J Cancer (2006) 95:339ā46.10.1038/sj.bjc.6603254
67
DeNardoDGCubaVLKimHWuKLeeAVBrownPH. Estrogen receptor DNA binding is not required for estrogen-induced breast cell growth. Mol Cell Endocrinol (2007) 277:13ā25.10.1016/j.mce.2007.07.006
68
SeelyJAmighKSSuzukiTMayhewBSasanoHGiguereVet alTranscriptional regulation of dehydroepiandrosterone sulfotransferase (SULT2A1) by estrogen-related receptor alpha. Endocrinology (2005) 146:3605ā13.10.1210/en.2004-1619
69
ApakTIDuffelMW. Interactions of the stereoisomers of alpha-hydroxytamoxifen with human hydroxysteroid sulfotransferase SULT2A1 and rat hydroxysteroid sulfotransferase STa. Drug Metab Dispos (2004) 32:1501ā8.10.1124/dmd.104.000919
70
SuzukiTMikiYMoriyaTShimadaNIshidaTHirakawaHet alEstrogen-related receptor alpha in human breast carcinoma as a potent prognostic factor. Cancer Res (2004) 64:4670ā6.10.1158/0008-5472.CAN-04-0250
71
GalindoCLMcCormickJFBubbVJAbid AlkademDHLiLSMcIverLJet alA long AAAG repeat allele in the 5ā UTR of the ERR-gamma gene is correlated with breast cancer predisposition and drives promoter activity in MCF-7 breast cancer cells. Breast Cancer Res Treat (2011) 130:41ā8.10.1007/s10549-010-1237-9
72
SiegelRNaishadhamDJemalA. Cancer statistics, 2013. CA Cancer J Clin (2013) 63:11ā30.10.3322/caac.21166
73
NyquistMDDehmSM. Interplay between genomic alterations and androgen receptor signaling during prostate cancer development and progression. Horm Cancer (2013) 4:61ā9.10.1007/s12672-013-0131-4
74
HugginsCHodgesCV. Studies on prostatic cancer. I. The effect of castration, of estrogen and androgen injection on serum phosphatases in metastatic carcinoma of the prostate. CA Cancer J Clin (1972) 22:232ā40.
75
FujimuraTTakahashiSUranoTOgawaSOuchiYKitamuraTet alDifferential expression of estrogen receptor beta (ERbeta) and its C-terminal truncated splice variant ERbetacx as prognostic predictors in human prostatic cancer. Biochem Biophys Res Commun (2001) 289:692ā9.10.1006/bbrc.2001.6038
76
HoSM. Estrogens and anti-estrogens: key mediators of prostate carcinogenesis and new therapeutic candidates. J Cell Biochem (2004) 91:491ā503.10.1002/jcb.10759
77
CheungCPYuSWongKBChanLWLaiFMWangXet alExpression and functional study of estrogen receptor-related receptors in human prostatic cells and tissues. J Clin Endocrinol Metab (2005) 90:1830ā44.10.1210/jc.2004-1421
78
FujimuraTTakahashiSUranoTKumagaiJOgushiTHorie-InoueKet alIncreased expression of estrogen-related receptor alpha (ERRalpha) is a negative prognostic predictor in human prostate cancer. Int J Cancer (2007) 120:2325ā30.10.1002/ijc.22363
79
FujimuraTTakahashiSUranoTIjichiNIkedaKKumagaiJet alDifferential expression of estrogen-related receptors beta and gamma (ERRbeta and ERRgamma) and their clinical significance in human prostate cancer. Cancer Sci (2010) 101:646ā51.10.1111/j.1349-7006.2009.01451.x
80
SuetsugiMSuLKarlsbergKYuanYCChenS. Flavone and isoflavone phytoestrogens are agonists of estrogen-related receptors. Mol Cancer Res (2003) 1:981ā91.
81
TremblayGBKunathTBergeronDLapointeLChampignyCBaderJAet alDiethylstilbestrol regulates trophoblast stem cell differentiation as a ligand of orphan nuclear receptor ERR beta. Genes Dev (2001) 15:833ā8.10.1101/gad.873401
82
CowardPLeeDHullMVLehmannJM. 4-Hydroxytamoxifen binds to and deactivates the estrogen-related receptor gamma. Proc Natl Acad Sci U S A (2001) 98(15):8880ā4.10.1073/pnas.151244398
83
TremblayGBBergeronDGiguereV. 4-Hydroxytamoxifen is an isoform-specific inhibitor of orphan estrogen-receptor-related (ERR) nuclear receptors beta and gamma. Endocrinology (2001) 142(10):4572ā5.10.1210/en.142.10.4572
84
ChaoWRAminKShiYHobbsPTanabeMTangaMet alSR16388: a steroidal antiangiogenic agent with potent inhibitory effect on tumor growth in vivo. Angiogenesis (2011) 14(1):1ā16.10.1007/s10456-010-9191-z
Summary
Keywords
estrogen-related receptors, estrogen receptors, estrogen, androgen, breast cancer, prostate cancer
Citation
Misawa A and Inoue S (2015) Estrogen-Related Receptors in Breast Cancer and Prostate Cancer. Front. Endocrinol. 6:83. doi: 10.3389/fendo.2015.00083
Received
12 March 2015
Accepted
05 May 2015
Published
26 May 2015
Volume
6 - 2015
Edited by
Jessica Kate Holien, St. Vincents Institute of Medical Research, Australia
Reviewed by
Maria Marino, Universita degli Studi Roma Tre, Italy; Domenico Iacopetta, University of Calabria, Italy
Copyright
Ā© 2015 Misawa and Inoue.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Satoshi Inoue, Department of Anti-Aging Medicine, Graduate School of Medicine, The University of Tokyo, 7-3-1 Hongo Bunkyo-ku, Tokyo 113-8655, Japan, inoue-ger@h.u-tokyo.ac.jp
Specialty section: This article was submitted to Cancer Endocrinology, a section of the journal Frontiers in Endocrinology
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.